A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps
Latest Information Update: 16 Sep 2026
At a glance
- Drugs Itepekimab (Primary) ; Mometasone
- Indications Rhinosinusitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
Most Recent Events
- 25 Aug 2026 Status changed from active, no longer recruiting to completed.
- 05 May 2026 Planned End Date changed from 9 Feb 2027 to 18 Aug 2026.
- 12 Mar 2026 This trial has been terminated early in Romania due to Sponsor Decision.